HC Wainwright initiated coverage on shares of TrovaGene (NASDAQ:TROV) in a report issued on Thursday, December 21st, Marketbeat Ratings reports. The firm issued a buy rating and a $1.00 price objective on the medical research company’s stock.
Other equities analysts have also issued research reports about the company. Maxim Group set a $4.00 price target on TrovaGene and gave the stock a buy rating in a research report on Wednesday, October 18th. downgraded TrovaGene from a buy rating to a hold rating in a report on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $3.70.
TrovaGene (NASDAQ:TROV) opened at $0.34 on Thursday. The company has a market capitalization of $17.84, a price-to-earnings ratio of -0.34 and a beta of 0.40. TrovaGene has a 52-week low of $0.23 and a 52-week high of $2.40.
TrovaGene (NASDAQ:TROV) last announced its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. The business had revenue of $0.12 million during the quarter. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%. analysts anticipate that TrovaGene will post -0.78 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the business. LMR Partners LLP bought a new stake in shares of TrovaGene during the 2nd quarter valued at about $151,000. Susquehanna International Group LLP grew its stake in shares of TrovaGene by 2,781.0% during the 2nd quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock valued at $174,000 after acquiring an additional 133,240 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of TrovaGene by 1,079.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock valued at $351,000 after acquiring an additional 254,601 shares during the period. Institutional investors and hedge funds own 9.91% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “HC Wainwright Initiates Coverage on TrovaGene (NASDAQ:TROV)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/14/trovagene-trov-now-covered-by-analysts-at-hc-wainwright.html.
TrovaGene Company Profile
Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.